J.M.J. Paulusse

J.M.J. Paulusse is an Associate Professor at the University of Twente, affiliated with the TechMed Centre, Biomolecular Nanotechnology, and the MESA+ Institute. His interdisciplinary research bridges polymer chemistry, nanotechnology, and biomedical applications, with a focus on drug delivery, targeted imaging, and sustainable chemical engineering.

His research interests span nanoparticles, polymer science, drug delivery systems, materials characterization, pharmacology, and sustainable chemistry. He develops advanced polymeric nanocarriers for medical applications, particularly in treating neurodegenerative diseases like Alzheimer’s by overcoming the blood-brain barrier. His work integrates synthetic chemistry with biomedical engineering to create functional, biodegradable, and imaging-capable nanomaterials.

The analysis of his recent publications reveals a strong trend in theranostic nanomaterials—systems that combine therapy and diagnostics—using stimuli-responsive polymers, polyphosphoesters, and click chemistry. His work increasingly emphasizes sustainability in chemical design and educational frameworks for systems thinking in green chemistry.

• Onderwijsprijs voor de opleiding Biomedische Technologie 2014
• 25th annual NBTE meeting Prize
• Proof-of-Concept Funding 2014
• Proof of Concept grant for startup QuantiS-dot bv (100 k€)
• ZONMW Grant 2014
• Recognition for Alzheimer’s and nanocarrier research

Dr. Paulusse has supervised several research projects and PhD candidates, as evidenced by collaborative publications and conference contributions. He has secured competitive grants, including ZONMW and proof-of-concept funding, supporting translational research and startup initiatives. His editorial and organizational roles in the European Symposium on Controlled Drug Delivery highlight his leadership in the field.

He is actively involved in the Biomolecular Nanotechnology group and the TechMed Centre, where his lab focuses on designing and characterizing functional polymer nanoparticles for biomedical applications. His team collaborates extensively across disciplines, including with clinicians and industry partners, to advance nanotherapeutics from concept to application.